After a three-year restructuring process, ICN Polfa Rzeszow, the Polish subsidiary of the US corporation Valeant Pharmaceuticals, has strengthened its position within the global organisation and become the exclusive representative of Valeant in Europe. In addition to the development of sales and production in Poland, the firm has also acquired Valeant subsidiaries in the Central European region and recently started operations in Romania and Bulgaria. In an interview with Pharma Poland News, Mariusz Gajowniczek, the company’s CEO, divulges the details of the company’s latest developments and future ventures.